In Focus: The Amyloid-Tau Relationship in the Pathophysiology of Alzheimer’s Disease
The content for this activity is based on the satellite symposium, In Focus: The Amyloid-Tau Relationship in the Pathophysiology of Alzheimer’s Disease that was presented at the The Alzheimer's Association International Conference® 2016 (AAIC®) on July 26, 2016. The pathophysiology of Alzheimer’s disease (AD) involves both amyloid and tau proteins; the exploration of the respective roles of these proteins in neuronal loss and neurodegeneration has important implications for future therapeutic interventions. PET imaging of amyloid and tau plays a critical role in understanding neurodegeneration patterns and clinical manifestations of AD.
This activity has been designed to meet the educational needs of care professionals involved in the diagnosis, treatment, or management of patients with AD.
Upon completion of this activity, participants will be better able to do the following:
- Define recent insights into the role of amyloid and tau proteins in the pathophysiology of AD
- Analyze the advances in imaging of amyloid and tau
Dennis J. Selkoe, MD (Program Chair)
David M. Holtzman, MD
William Jagust, MD
Disclosure of Conflicts of Interest
Canadian Neurological Society (CNS) requires all individuals who are in a position to control the content of this activity to disclose any financial relationships with commercial interests/conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to Canadian Neurological Society policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
During the past two years, the following faculty have been or currently are affiliated with the following commercial interests:
Name of Faculty or Presenter
Relationship Identified With:
David M. Holtzman, MD
Consultant/Advisor: AbbVie Inc; C2N Diagnostics, LLC; Denali Therapeutics Inc; Eli Lilly and Company; Genentech, Inc; Neurophage
Grant/Research Support: AbbVie Inc; C2N Diagnostics, LLC; Denali Therapeutics Inc; Eli Lilly and Company
Stock Owner: C2N Diagnostics, LLC
William Jagust, MD
Consultant/Advisor: Banner Alzheimer Institute; Bioclinica; Genentech, Inc; Novartis AG
Dennis J. Selkoe, MD
Consultant/Advisor: Prothena Biosciences
Stock Owner: Prothena Biosciences
Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Lyerka Miller, PHD, and Dan Morin hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past two years.
This CME activity has been peer-reviewed by Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
This activity has been supported by an independent educational grant from Eli Lilly Canada Inc.
Jointly provided by the Canadian Neurological Society, The Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.
CME Credit (Physicians)
This program was developed by the Canadian Neurological Society and was planned to achieve scientific integrity, objectivity and balance. This program is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Neurological Society, for up to a maximum of 1.5 hours of Section 1 credits.
Credit certificates for this activity are provided by the Canadian Neurological Society. The activity is planned in collaboration by the Canadian Neurological Society, the Elsevier Office of Continuing Medical Education, and Miller Medical Communications, LLC.
Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Read more on the Royal College agreements www.royalcollege.ca.
The In Focus: The Amyloid-Tau Relationship in the Pathophysiology of Alzheimer’s Disease, made available on http://courses.elseviercme.com/aaic2016/627e and organized by the Canadian Neurological Society, The Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.
The In Focus: The Amyloid-Tau Relationship in the Pathophysiology of Alzheimer’s Disease, made available on http://courses.elseviercme.com/aaic2016/627e and organized by the Canadian Neurological Society, The Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC, is awarded 1 European CME credits (ECMEC's).
Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Canadian Neurological Society, the Elsevier Office of Continuing Medical Education, and Miller Medical Communications, LLC., and Eli Lilly Canada Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.50 RCPSC section 1 MOC credits
- 1.00 EACCME